

CLAIMS

1. An isolated antibody or antigen-binding fragment thereof which specifically binds to CD73 comprising an antibody V_L and an antibody V_H, wherein the V_L comprises the amino acid sequence comprising SEQ ID NO: 68; and wherein the V_H comprises the amino acid sequence comprising SEQ ID NO: 82.
2. An isolated antibody or antigen-binding fragment thereof which specifically binds to CD73 comprising a V_L and a V_H comprising VL-CDR1, VL-CDR2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3, wherein VL-CDR1 comprises SEQ ID NO: 46, VL-CDR2 comprises SEQ ID NO: 51, VL-CDR3 comprises SEQ ID NO: 56, VH-CDR1 comprises SEQ ID NO: 36, VH-CDR2 comprises SEQ ID NO: 39, and VH-CDR3 comprises SEQ ID NO: 45.
3. The isolated antibody or antigen-binding fragment thereof according to either one of claims 1 or 2, which comprises a heavy chain constant region or fragment thereof.
4. The isolated antibody or antigen-binding fragment thereof according to either one of claims 1 or 2, which is an antagonist of CD73.
5. The isolated antibody or antigen-binding fragment thereof according to claim 4, wherein the CD73 is human CD73.
6. The isolated antibody or antigen-binding fragment thereof of claims 1 or 2 for use as a medicament.
7. The isolated antibody or antigen-binding fragment thereof of claims 1 or 2 for use in therapy.

8. A pharmaceutical formulation comprising an effective amount of an anti-CD73 antibody, or antigen binding fragment thereof and an anti-PD-L1 antibody, or an antigen binding fragment thereof, wherein the anti-CD73 antibody is MEDI9447, Phen0203 hIgG1, or an antigen binding fragment thereof.
9. The pharmaceutical formulation of claim 8, wherein the anti-PD-L1 is MEDI4736, BMS-936559, or MPDL3280A, or an antigen binding fragment thereof.
10. A pharmaceutical formulation comprising an effective amount of an anti-CD73 antibody, or an antigen binding fragment thereof and anti-CTLA4 antibody, or an antigen binding fragment thereof, wherein the anti-CD73 antibody is MEDI9447, Phen0203 hIgG1, or an antigen binding fragment thereof.
11. The pharmaceutical formulation of claim 10, wherein the anti-CTLA4 antibody is ipilimumab or tremelimumab (ticilimumab, CP-675,206) or an antigen binding fragment thereof.